Ifsamide-M Injection is a sterile, injectable formulation combining Mesna (100 mg/ml) and Ifosfamide (1 g) designed for intravenous administration in oncological therapy. Ifosfamide, an alkylating agent, exerts cytotoxic effects by cross-linking DNA strands, thereby inhibiting DNA synthesis and inducing apoptosis in rapidly dividing malignant cells. Mesna serves as a uroprotective agent, effectively binding and detoxifying acrolein, a toxic metabolite of Ifosfamide, thus preventing hemorrhagic cystitis and other urothelial toxicities commonly associated with Ifosfamide therapy. The combination enhances therapeutic efficacy while minimizing adverse effects related to bladder toxicity. Ifsamide-M Injection is indicated for the treatment of various malignancies, including sarcomas, lymphomas, and testicular cancer, either as monotherapy or in combination with other chemotherapeutic agents. Dosage and administration should be individualized based on patient condition, tumor type, and treatment protocol, with careful monitoring of renal function, hematologic parameters, and hydration status. Adverse reactions may include myelosuppression, neurotoxicity, nephrotoxicity, and gastrointestinal disturbances. Appropriate supportive care and monitoring are essential to optimize treatment outcomes. This combination injection should be administered under strict medical supervision in a hospital or specialized oncology setting.